XTL Biopharmaceuticals Ltd Working Capital to Net Assets Ratio
XTL Biopharmaceuticals Ltd working capital to net assets ratio. XTL Biopharmaceuticals Ltd (XTLB) has a Working Capital to Net Assets ratio of -16.0% as of December 2024. Working capital of ILA-867.00K (current assets of ILA1.34 Million minus current liabilities of ILA2.21 Million) is measured against net assets of ILA5.43 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check XTL Biopharmaceuticals Ltd (XTLB) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of XTL Biopharmaceuticals Ltd (2013–2024)
Working capital to net assets ratio of XTL Biopharmaceuticals Ltd from 2013 to 2024. This chart shows how XTL Biopharmaceuticals Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of December 2024, the ratio stands at -16.0%, reflecting working capital of ILA-867.00K against net assets of ILA5.43 Million ILA. See XTLB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
XTL Biopharmaceuticals Ltd Working Capital to Net Assets Ratio by Year (2013–2024)
XTL Biopharmaceuticals Ltd working capital to net assets ratio by year from 2013 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for XTL Biopharmaceuticals Ltd from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see XTL Biopharmaceuticals Ltd total assets.
| Year | WC/NA Ratio | Working Capital (ILA) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -16.0% | ILA-867.00K | ILA5.43 Million | ILA1.34 Million | ILA2.21 Million | ▼ -98.8 pp |
| 2023 | 82.9% | ILA1.84 Million | ILA2.22 Million | ILA2.05 Million | ILA206.00K | ▼ -7.6 pp |
| 2022 | 90.5% | ILA3.62 Million | ILA4.00 Million | ILA3.81 Million | ILA187.00K | ▼ -22.1 pp |
| 2021 | 112.6% | ILA6.01 Million | ILA5.33 Million | ILA6.24 Million | ILA231.00K | ▲ +18.7 pp |
| 2020 | 93.9% | ILA5.87 Million | ILA6.25 Million | ILA6.12 Million | ILA254.00K | ▼ -0.6 pp |
| 2019 | 94.5% | ILA6.60 Million | ILA6.98 Million | ILA6.83 Million | ILA232.00K | ▼ -0.9 pp |
| 2018 | 95.4% | ILA7.94 Million | ILA8.32 Million | ILA8.20 Million | ILA253.00K | ▼ -67.8 pp |
| 2017 | 163.2% | ILA5.91 Million | ILA3.62 Million | ILA6.21 Million | ILA300.00K | ▲ +73.0 pp |
| 2016 | 90.2% | ILA2.42 Million | ILA2.69 Million | ILA2.75 Million | ILA330.00K | ▲ +11.9 pp |
| 2015 | 78.4% | ILA3.83 Million | ILA4.89 Million | ILA4.26 Million | ILA436.00K | ▲ +32.7 pp |
| 2014 | 45.7% | ILA2.14 Million | ILA4.68 Million | ILA3.10 Million | ILA965.00K | ▼ -11.4 pp |
| 2013 | 57.0% | ILA3.87 Million | ILA6.79 Million | ILA5.09 Million | ILA1.22 Million | — |